论文部分内容阅读
目的了解海门市耐多药肺结核患者治疗管理效果,分析防治效果。方法对2009年10月至2013年9月确诊并接受治疗患者统一用6CmZPasPtoLfx/18ZpasPtoLfx方案化疗,对结果进行分析。结果 4年共发现耐多药肺结核37例,接受治疗28例(75.7%)。治愈12例(42.9%),完成疗程2例(7.1%),治疗成功14例(50.0%),治疗失败3例(10.7%),产生药物不良反应13例(46.4%),中断治疗6例(21.4%),死亡5例(17.9%)。不同性别、是否合并空洞、初治与复治、住院和门诊相结合与单一门诊治疗的治愈率差异均无统计学意义。结论对耐多药肺结核患者规范化抗结核治疗和DOT管理,可取得较满意疗效。
Objective To understand the effect of treatment and management of MDR-TB patients in Haimen and to analyze the effect of prevention and treatment. Methods The patients diagnosed and treated from October 2009 to September 2013 were treated with 6CmZPasPtoLfx / 18ZpasPtoLfx regimen and the results were analyzed. Results A total of 37 MDR-TB cases were found in 4 years and 28 cases (75.7%) were treated. 12 cases (42.9%) were cured, 2 cases completed the treatment (7.1%), 14 cases (50.0%) were successful in treatment, 3 cases (10.7%) failed treatment, 13 cases (46.4% (21.4%) and 5 deaths (17.9%). There was no significant difference in the cure rates between different sexes, whether there was a merger or not, initial treatment and retreatment, inpatient and outpatient treatment and single outpatient treatment. Conclusions The standardized anti-tuberculosis and DOT management of MDR-TB patients can achieve more satisfactory results.